Form 4: Zentalis Pharmaceuticals' Chief Scientific Officer Sells Shares to Cover Tax Obligations
SEC Form 4
Mark Lackner, Chief Scientific Officer of Zentalis Pharmaceuticals, sold 4,411 shares of common stock on January 2, 2025, to cover tax withholding obligations related to vested restricted stock units.
Summary
- On January 2, 2025, Mark Lackner, the Chief Scientific Officer of Zentalis Pharmaceuticals, sold 4,411 shares of the company's common stock.
- The sale was executed at a price of $3.12 per share.
- This transaction was conducted automatically by the issuer to cover tax withholding obligations associated with the vesting and settlement of restricted stock units previously granted to Mr. Lackner.
- Following the transaction, Mr. Lackner directly owns 191,317 shares of Zentalis Pharmaceuticals.
Sentiment
Score: 6
Explanation: The document describes a routine transaction (sale of shares to cover taxes) and doesn't contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among company executives and employees.
Stakeholder Impact
- The sale has a minimal impact on shareholders as it is a small transaction related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of the stock sale transaction. |
| 01/03/2025 | Date of signature on the SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.